Flexion Therapeutics, Inc. (NASDAQ:FLXN)‘s stock had its “outperform” rating restated by equities researchers at Royal Bank Of Canada in a research report issued on Thursday. They presently have a $44.00 target price on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 102.11% from the company’s previous close.

FLXN has been the topic of several other reports. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Janney Montgomery Scott reaffirmed a “buy” rating and set a $35.00 price target (up from $30.00) on shares of Flexion Therapeutics in a research report on Wednesday, July 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 price target on shares of Flexion Therapeutics in a research report on Monday, May 15th. Finally, BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $31.10.

Flexion Therapeutics (FLXN) opened at 21.77 on Thursday. Flexion Therapeutics has a one year low of $15.44 and a one year high of $29.41. The firm’s market capitalization is $691.35 million. The stock has a 50 day moving average of $22.41 and a 200 day moving average of $21.21.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by $0.11. Analysts forecast that Flexion Therapeutics will post ($3.56) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Flexion Therapeutics, Inc. (NASDAQ:FLXN) Earns Outperform Rating from Royal Bank Of Canada” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/flexion-therapeutics-inc-nasdaqflxn-earns-outperform-rating-from-royal-bank-of-canada.html.

In other Flexion Therapeutics news, insider Michael D. Clayman purchased 5,000 shares of Flexion Therapeutics stock in a transaction on Monday, June 5th. The shares were purchased at an average cost of $17.23 per share, with a total value of $86,150.00. Following the completion of the transaction, the insider now directly owns 20,146 shares in the company, valued at approximately $347,115.58. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark Stejbach purchased 1,580 shares of Flexion Therapeutics stock in a transaction on Friday, June 16th. The shares were acquired at an average cost of $17.02 per share, for a total transaction of $26,891.60. The disclosure for this purchase can be found here. Insiders own 15.98% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. raised its stake in Flexion Therapeutics by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock worth $2,047,000 after buying an additional 513 shares in the last quarter. IFP Advisors Inc raised its stake in Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,000 shares in the last quarter. Teachers Advisors LLC raised its stake in Flexion Therapeutics by 3.1% in the first quarter. Teachers Advisors LLC now owns 44,796 shares of the specialty pharmaceutical company’s stock worth $1,205,000 after buying an additional 1,328 shares in the last quarter. Alps Advisors Inc. raised its stake in Flexion Therapeutics by 7.1% in the second quarter. Alps Advisors Inc. now owns 28,666 shares of the specialty pharmaceutical company’s stock worth $580,000 after buying an additional 1,888 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its stake in Flexion Therapeutics by 5.7% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 55,853 shares of the specialty pharmaceutical company’s stock worth $1,503,000 after buying an additional 3,003 shares in the last quarter. Institutional investors own 75.43% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.